Janney Montgomery Scott LLC boosted its holdings in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 11.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,207,278 shares of the company’s stock after acquiring an additional 124,417 shares during the quarter. AbbVie accounts for about 0.6% of Janney Montgomery Scott LLC’s portfolio, making the stock its 23rd largest position. Janney Montgomery Scott LLC’s holdings in AbbVie were worth $262,571,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Diamant Asset Management Inc. raised its stake in shares of AbbVie by 21,649.0% during the first quarter. Diamant Asset Management Inc. now owns 3,671,231 shares of the company’s stock valued at $798,456,000 after acquiring an additional 3,654,351 shares during the last quarter. Kenora Financial LLC lifted its holdings in shares of AbbVie by 4.7% during the first quarter. Kenora Financial LLC now owns 3,510 shares of the company’s stock worth $763,000 after purchasing an additional 156 shares during the period. apricus wealth LLC grew its stake in shares of AbbVie by 1.4% in the first quarter. apricus wealth LLC now owns 20,904 shares of the company’s stock worth $4,546,000 after purchasing an additional 295 shares during the last quarter. CrossGen Wealth LLC grew its stake in shares of AbbVie by 7.1% in the first quarter. CrossGen Wealth LLC now owns 5,480 shares of the company’s stock worth $1,192,000 after purchasing an additional 363 shares during the last quarter. Finally, Caldwell Trust Co increased its holdings in AbbVie by 4.4% in the first quarter. Caldwell Trust Co now owns 25,513 shares of the company’s stock valued at $5,549,000 after purchasing an additional 1,064 shares during the period. 70.23% of the stock is currently owned by institutional investors and hedge funds.
AbbVie Price Performance
Shares of NYSE:ABBV opened at $251.52 on Monday. AbbVie Inc. has a 1 year low of $181.73 and a 1 year high of $253.35. The business’s 50-day moving average is $215.16 and its 200-day moving average is $219.16. The company has a market capitalization of $444.38 billion, a price-to-earnings ratio of 123.90, a P/E/G ratio of 0.77 and a beta of 0.32.
AbbVie Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.8%. AbbVie’s dividend payout ratio (DPR) is 340.89%.
Wall Street Analysts Forecast Growth
Several brokerages have commented on ABBV. BMO Capital Markets reaffirmed an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Sanford C. Bernstein reissued a “market perform” rating on shares of AbbVie in a research note on Tuesday, June 23rd. Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a research report on Monday, June 8th. William Blair reaffirmed an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. Finally, Guggenheim reiterated a “buy” rating and issued a $249.00 target price on shares of AbbVie in a report on Friday, May 1st. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $253.81.
Get Our Latest Research Report on ABBV
Key Stories Impacting AbbVie
Here are the key news stories impacting AbbVie this week:
- Positive Sentiment: AbbVie said the FDA approved Skyrizi for pediatric use in psoriatic disease, making it the first and only IL-23 inhibitor in the U.S. approved for children six years and older weighing less than 40 kg with plaque psoriasis or psoriatic arthritis. The expansion broadens the drug’s addressable market and supports long-term sales growth. Article: SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease
- Positive Sentiment: AbbVie’s Apogee Therapeutics acquisition is being viewed favorably by analysts, with Canaccord raising its price target and saying the deal strengthens AbbVie’s long-term growth outlook by adding promising pipeline assets. Article: AbbVie Just Sparked a 46% Rally in Apogee. Here’s Why This $10.9 Billion Deal Could Be a Win for AbbVie Investors.
- Positive Sentiment: AbbVie is also benefiting from broader healthcare sector strength, with shares hitting new highs as investors rotate into defensive large-cap pharma names. Article: Lilly, J&J, AbbVie hit all-time highs as healthcare outperforms
- Neutral Sentiment: AbbVie announced it will host its second-quarter 2026 earnings call on July 31, which is a standard investor update and does not by itself change fundamentals. Article: AbbVie to Host Second-Quarter 2026 Earnings Conference Call
- Neutral Sentiment: Commentary pieces also highlighted AbbVie’s recent pediatric label expansions in Europe for Skyrizi and Maviret, reinforcing the company’s shift toward earlier-disease and younger-patient growth opportunities. Article: Will AbbVie’s (ABBV) Pediatric Expansions Reveal a Deeper Shift in Its Growth Mix?
About AbbVie
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.
Featured Articles
- Five stocks we like better than AbbVie
- As Stablecoins Keep Growing, These 2 Stocks Benefit
- Apple Just Handed These 4 Memory Stocks Their Best News of the Year
- Costco’s Secret Growth Engine May Be Running Out of Gas
- Why Alphabet’s Pullback May Be an Opportunity in Disguise
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
